Amgen Inc. (AMGN)
NASDAQ: AMGN · Real-Time Price · USD
272.11
+2.68 (0.99%)
Jan 17, 2025, 4:00 PM EST - Market closed
Amgen Revenue
Amgen had revenue of $8.50B in the quarter ending September 30, 2024, with 23.18% growth. This brings the company's revenue in the last twelve months to $32.53B, up 21.25% year-over-year. In the year 2023, Amgen had annual revenue of $28.19B with 7.09% growth.
Revenue (ttm)
$32.53B
Revenue Growth
+21.25%
P/S Ratio
4.49
Revenue / Employee
$1,218,502
Employees
26,700
Market Cap
146.27B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 28.19B | 1.87B | 7.09% |
Dec 31, 2022 | 26.32B | 344.00M | 1.32% |
Dec 31, 2021 | 25.98B | 555.00M | 2.18% |
Dec 31, 2020 | 25.42B | 2.06B | 8.83% |
Dec 31, 2019 | 23.36B | -385.00M | -1.62% |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Dec 31, 2014 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 400.28B |
Johnson & Johnson | 87.70B |
Merck & Co. | 63.17B |
AbbVie | 55.53B |
AstraZeneca | 51.21B |
Novartis AG | 49.94B |
Thermo Fisher Scientific | 42.37B |
Abbott Laboratories | 41.22B |
AMGN News
- 3 days ago - FDA APPROVES LUMAKRAS® (SOTORASIB) IN COMBINATION WITH VECTIBIX® (PANITUMUMAB) FOR CHEMOREFRACTORY KRAS G12C-MUTATED METASTATIC COLORECTAL CANCER - PRNewsWire
- 3 days ago - US FDA approves Amgen's colorectal cancer therapy - Reuters
- 6 days ago - Amgen Inc. (AMGN) 43rd Annual J.P. Morgan Healthcare Conference 2025 (Transcript) - Seeking Alpha
- 6 days ago - Top 5 Cancer Pharma Stocks With Strong Risk/Reward In 2025 - Seeking Alpha
- 11 days ago - AMGEN TO PRESENT AT 43RD ANNUAL J.P. MORGAN HEALTHCARE CONFERENCE - PRNewsWire
- 12 days ago - Healthy Returns: The FDA approved fewer new drugs in 2024 — but some big ones hit the market - CNBC
- 12 days ago - Asher Bio Announces Clinical Trial Collaboration and Supply Agreement on Etakafusp Alfa (AB248) in Combination with Bispecific T-cell Engager in Patients with Small Cell Lung Cancer - Business Wire
- 14 days ago - Amgen: The Buying Opportunity Has Now Arrived (Rating Upgrade) - Seeking Alpha